Opdivo (Nivolumab) vs Cyramza (ramucirumab)

Opdivo (nivolumab) is an immune checkpoint inhibitor that works by blocking the PD-1 pathway, which in turn helps the immune system to attack cancer cells; it's commonly used for various types of cancer, including melanoma, lung cancer, and kidney cancer. Cyramza (ramucirumab), on the other hand, is a vascular endothelial growth factor (VEGF) Receptor 2 antagonist that works by inhibiting the blood supply to tumors and is typically used for gastric cancer, colorectal cancer, and non-small cell lung cancer. When deciding between Opdivo and Cyramza, it's crucial to consider the specific type of cancer, the stage of the disease, the patient's overall health, and the treatment's side effect profile, and this decision should be made in close consultation with an oncologist who can tailor the treatment plan to the individual's unique needs.

Difference between Opdivo and Cyramza

Metric	Opdivo (Nivolumab)	Cyramza (ramucirumab)
Generic name	Nivolumab	Ramucirumab
Indications	Various types of cancers, including melanoma, lung cancer, kidney cancer, bladder cancer, head and neck cancers, and others.	Gastric cancer, non-small cell lung cancer, colorectal cancer, and hepatocellular carcinoma.
Mechanism of action	PD-1 receptor blocker that prevents PD-1 from binding to its ligands, PD-L1 and PD-L2, which may help restore the immune system’s ability to fight cancer.	VEGFR2 antagonist that inhibits angiogenesis, which can limit tumor growth by reducing the tumor's blood supply.
Brand names	Opdivo	Cyramza
Administrative route	Intravenous infusion	Intravenous infusion
Side effects	Fatigue, rash, musculoskeletal pain, pruritus, diarrhea, nausea, and possible immune-mediated side effects.	Hypertension, diarrhea, headache, and infusion-related reactions.
Contraindications	Known hypersensitivity to nivolumab or any of its excipients.	Known hypersensitivity to ramucirumab or any of its excipients.
Drug class	Immune checkpoint inhibitor	Monoclonal antibody
Manufacturer	Bristol Myers Squibb	Eli Lilly and Company

Efficacy

Introduction to Opdivo (Nivolumab) in Lung Cancer Treatment

Opdivo, also known by its generic name Nivolumab, is a medication that has shown efficacy in the treatment of certain types of lung cancer. It is a type of immunotherapy that works by blocking the programmed death-1 (PD-1) pathway, which is a pathway that cancer cells often exploit to avoid being attacked by the body's immune system. By inhibiting this pathway, Opdivo helps the immune system to better recognize and destroy cancer cells. It has been approved for use in patients with non-small cell lung cancer (NSCLC) after chemotherapy has failed, and in certain cases, it is used as a first-line treatment.

Effectiveness of Opdivo in Clinical Trials

Clinical trials have demonstrated the efficacy of Opdivo in improving the survival rates of lung cancer patients. In a pivotal study known as CheckMate-057, patients with advanced NSCLC who had progressed during or after chemotherapy showed a significant improvement in overall survival when treated with Opdivo compared to those who received docetaxel, a standard chemotherapy drug. The median overall survival was notably higher in the Opdivo group. Moreover, Opdivo has been shown to have a durable response in some patients, meaning that the effects of the treatment can last even after the therapy has been completed.

Introduction to Cyramza (Ramucirumab) in Lung Cancer Treatment

Cyramza, with the generic name ramucirumab, is another medication used in the treatment of lung cancer, specifically for advanced or metastatic non-small cell lung cancer. Cyramza is a vascular endothelial growth factor receptor 2 (VEGFR2) antagonist, which works by inhibiting the blood supply that tumors need to grow and spread. It is often used in combination with docetaxel after other treatments have failed. Cyramza has been shown to provide a modest improvement in survival rates for NSCLC patients when added to chemotherapy.

Effectiveness of Cyramza in Clinical Trials

The efficacy of Cyramza was evaluated in a large clinical trial known as REVEL, which included patients with advanced NSCLC who had progressed after initial chemotherapy treatment. The study found that adding Cyramza to docetaxel chemotherapy significantly improved overall survival compared to chemotherapy alone. The median survival was increased, and the progression-free survival was also improved, indicating that the combination of Cyramza and chemotherapy could offer an advantage over chemotherapy alone in this patient population. However, it is important to note that the benefits must be weighed against the potential risks and side effects associated with the treatment.

Regulatory Agency Approvals

Opdivo

European Medical Agency (EMA), European Union
Food and Drug Administration (FDA), USA
Health Canada
Pharmaceuticals and Medical Devices Agency (PMDA), Japan
Therapeutic Goods Administration (TGA), Australia
Medsafe (NZ)

Cyramza

European Medical Agency (EMA), European Union
Food and Drug Administration (FDA), USA
Health Canada
Therapeutic Goods Administration (TGA), Australia
Medsafe (NZ)

Access Opdivo or Cyramza today

If Opdivo or Cyramza are not approved or available in your country (e.g. due to supply issues), you can access them via Everyone.org.

Buy Opdivo

Buy Cyramza

How it works

Make an enquiry

Choose the medicine you want to buy, answer a couple of questions, and upload your prescription to speed things up. We’ll get back to you within 24 hours.

Breeze through the paperwork

We'll guide you through the required documents for importing unapproved medicine, ensuring you have all the necessary information.

Get a personalized quote

We’ll prepare a quote for you, including medicine costs and any shipping, administrative, or import fees that may apply.

Receive your medicine

Accept the quote and we’ll handle the rest - sourcing and safely delivering your medicine.

Some text on this page has been automatically generated. Speak to your physician before you start a new treatment or medication.

Let's talk

If you have any questions, call us or send us a message through WhatsApp or email: